Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor correct obesity, dyslipidemia and nephropathy in rodent animals.

Abstract

OBJECTIVE:

Glucose-dependent insulinotropic polypeptide receptor (GIPR) has been identified as a contributor to obesity, and GIPR knockout mice are protected against diet-induced obesity (DIO). Therefore, we developed the anti-GIPR antagonistic monoclonal antibody (mAb) alone and in combination with DPP-4 inhibitor as potential therapeutic strategy for treating obesity and dyslipidemia based on this genetic evidence.

METHODS:

Fully neutralized GIPR activity of GIPR-monoclonal antibody (mAb) was assessed by regulating the in vitro production of cAMP in the mouse GIPR stably expressing cells. Chronic efficacies of GIPR-mAb alone and in combination with DPP-4 inhibitor Sitagliptin in diabetic or DIO mice were both investigated. Multiple metabolic parameters including body weight, glucose level, fat mass, lipid metabolism-related indicators as well as H&E staining and immunohistochemical analysis were performed. Role of GIPR in pancreatic cells on regulating fat metabolism was explored in GIPR β-cell knockout mouse model.

RESULTS:

Chronic treatment of GIPR-mAb improved body weight control, glucose metabolism, and was associated with reduced fat mass, enhanced pancreatic function and exchange ratio of the resting respiratory in diabetic mice. In addition, further study of anti-GIPR mAb combined with Sitagliptin in DIO mice demonstrated significantly improved weight loss compare to the both monomer treatment. Furthermore, we demonstrated important role of GIPR in β-cell in regulating the fat mass and response to antagonistic GIPR-mAb in a conditional GIPR-knockout mouse.

CONCLUSION:

Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor provide preclinical therapeutic approaches to treat obesity.

• Authors: Jiawei Chen, Songsong Zheng, Yongbin Hu, Xin Mou, Huiyang Wang
• Journal: Life sciences (Life Sci) Vol. 269 Pg. 119038 (Mar 15 2021) ISSN: 1879-0631 [Electronic] Netherlands
• PMID: 33453239 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier Inc. All rights reserved.

Chemical References

• Antibodies, Monoclonal
• Dipeptidyl-Peptidase IV Inhibitors
• Receptors, Gastrointestinal Hormone
• gastric inhibitory polypeptide receptor
• Dipeptidyl Peptidase 4

Topics

• Animals
• Antibodies, Monoclonal (pharmacology)
• Body Weight
• Diet, High-Fat (adverse effects)
• Dipeptidyl Peptidase 4 (chemistry)
• Dipeptidyl-Peptidase IV Inhibitors (pharmacology)
• Drug Therapy, Combination
• Dyslipidemias (drug therapy, etiology, pathology)
• Kidney Diseases (drug therapy, etiology, pathology)
• Male
• Mice
• Mice, Knockout
• Mice, Obese
• Obesity (drug therapy, etiology, pathology)
• Receptors, Gastrointestinal Hormone (antagonists & inhibitors, immunology, physiology)
• Weight Loss